KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Operating Expenses (2022 - 2025)

Recursion Pharmaceuticals' Other Operating Expenses history spans 4 years, with the latest figure at $14.3 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 11.58% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $71.0 million, up 56.84%, while the annual FY2025 figure was $71.0 million, 56.84% up from the prior year.
  • Other Operating Expenses reached $14.3 million in Q4 2025 per RXRX's latest filing, down from $14.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $21.8 million in Q1 2025 to a low of $7.8 million in Q1 2022.
  • Average Other Operating Expenses over 4 years is $12.9 million, with a median of $12.3 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: plummeted 34.05% in 2023, then surged 119.17% in 2025.
  • A 4-year view of Other Operating Expenses shows it stood at $10.8 million in 2022, then decreased by 8.85% to $9.9 million in 2023, then increased by 29.48% to $12.8 million in 2024, then grew by 11.58% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Other Operating Expenses are $14.3 million (Q4 2025), $14.7 million (Q3 2025), and $20.2 million (Q2 2025).